BCL2 and post-transplant lymphoproliferative disease: Overexpression of BCL‐2 has been found, for example, in LCL and type III BL cell lines [16], as well as in EBV‐positive lymphoproliferative disorders harboring type III latency, including PTLD [17, 18].